Scarica l'app Stockscreener
14.92
3.37%
-0.52
Dopo l'orario di chiusura:
14.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.44
Aprire:
$15.27
Volume 24 ore:
1.19M
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.24B
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-8.1978
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-17.11%
1M Prestazione:
+16.11%
6M Prestazione:
+11.93%
1 anno Prestazione:
+102.99%
Intervallo 1D:
$14.88
$15.64
Intervallo di 1 settimana:
$14.88
$17.98
Portata 52W:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.92 | 1.29B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com Nigeria
Aug Breakouts: Can EyePoint Pharmaceuticals Inc expand its profit margins2026 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
EyePoint (EYPT) Sees Target Price Raise by Citigroup to $35 | EY - GuruFocus
EyePoint stock rating maintained at Outperform by Mizuho - Investing.com
EyePoint Reports Fourth-Quarter and Full-Year 2025 Financial Results, Provides Corporate Update - VisionMonday.com
(EYPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP - MarketBeat
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - AOL.com
Decoding EyePoint Inc (EYPT): A Strategic SWOT Insight - GuruFocus
Is It Too Late To Consider EyePoint (EYPT) After Its 173% One Year Surge? - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
Earnings Summary: EyePoint (EYPT) Q4 2025 net loss widens - AlphaStreet
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint Q4 2025 Financial Results: Net Loss of $67.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position By Investing.com - Investing.com South Africa
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
EYPT (EyePoint) ROE % : -107.10% (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):